Adding carboplatin to hormone therapy for metastatic prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests whether adding a chemotherapy drug called carboplatin to standard hormone therapy can help men with prostate cancer that has spread and has either a BRCA gene change or neuroendocrine features. The goal is to see if this combination slows the cancer and improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have prostate cancer that has spread to bones, lymph nodes, or other parts of the body.
- You have either a BRCA gene mutation (a specific genetic change) or your cancer shows neuroendocrine features (a certain type of cell pattern seen under a microscope).
- You have not had surgery or radiation to treat your prostate cancer in the past (a minor procedure called TURP is allowed).
- You have not had chemotherapy for prostate cancer before, and you are able to receive a chemotherapy drug called docetaxel.
- You are between 18 and 80 years old and your overall health is good (able to care for yourself, with some limitations allowed).
- Your kidney and liver function meet certain minimum levels (checked with blood tests).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a new drug (saruparib) to standard radiation and hormone therapy can help prevent prostate cancer from spreading to other parts of the body. It is for men with high-risk prostate cancer that has a BRCA gene mutation.
This trial tests whether removing the prostate (surgery) plus standard hormone therapy and chemotherapy can help men whose prostate cancer has spread to many places in the body. It is for men who have not yet had treatment for their cancer.
This trial looks at combining hormone therapy with either chemotherapy (docetaxel), a targeted pill (like abiraterone or enzalutamide), or radiation to the prostate tumor for men whose prostate cancer has spread but is still sensitive to hormones. The goal is to see which approach works best for controlling the cancer.
This trial tests giving the chemotherapy drug carboplatin before surgery to treat people with high-risk prostate cancer and an inherited BRCA1 or BRCA2 gene change. The goal is to shrink or control the cancer before an operation and improve outcomes.
This study tests whether adding a chemotherapy drug called carboplatin to another chemotherapy called cabazitaxel works better than cabazitaxel alone for men with advanced prostate cancer that has spread and no longer responds to hormone therapy. All participants must have already had docetaxel chemotherapy.
This trial is for men with metastatic prostate cancer that has already spread beyond the pelvis. It tests whether adding a chemotherapy drug (docetaxel) to the usual hormone therapy plus apalutamide can help control the cancer better than hormone therapy alone.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.